Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.3.1.900
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Consolidated Statements Of Operations    
Revenues
Operating expenses:    
Amortization & depreciation $ 454 $ 776
General and administrative 446,983 505,552
Total operating expenses 447,437 506,328
Loss from operations (447,437) (506,328)
Other income (expense):    
Gain/(Loss) on fair value adjustment - derivatives 25,456 $ (21,559)
Gain on debt reversal 485
Interest expense (251,500) $ (188,046)
Interest expense - beneficial conversion feature (23,750) (32,996)
Total other income (expense) (249,309) (242,601)
Loss before provision for income taxes $ (696,746) $ (748,929)
Provision for income tax
Net loss $ (696,746) $ (748,929)
Less: Net loss attributable to noncontrolling interest 5,012 4,367
Net loss attributable to TranBioTec, Inc. $ (691,734) $ (744,562)
Net loss per share    
(Basic and fully diluted) $ (0.01) $ (0.02)
Weighted average number of common shares outstanding 59,261,114 39,215,919